-$0.28 Earnings Per Share Expected for Seelos Therapeutics, Inc. (NASDAQ:SEEL) This Quarter

Equities analysts expect that Seelos Therapeutics, Inc. (NASDAQ:SEELGet Rating) will post earnings per share of ($0.28) for the current quarter, according to Zacks. Zero analysts have made estimates for Seelos Therapeutics’ earnings. Seelos Therapeutics also reported earnings per share of ($0.28) during the same quarter last year. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Seelos Therapeutics will report full year earnings of ($0.90) per share for the current financial year, with EPS estimates ranging from ($1.17) to ($0.63). For the next financial year, analysts expect that the firm will post earnings of ($1.03) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Seelos Therapeutics.

SEEL has been the topic of a number of research analyst reports. Zacks Investment Research cut Seelos Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 17th. B. Riley reduced their target price on Seelos Therapeutics from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday, March 14th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Seelos Therapeutics has a consensus rating of “Buy” and a consensus price target of $6.50.

In related news, insider Raj Mehra acquired 66,667 shares of Seelos Therapeutics stock in a transaction dated Thursday, March 31st. The shares were purchased at an average cost of $0.85 per share, with a total value of $56,666.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in shares of Seelos Therapeutics by 2.8% in the fourth quarter. BlackRock Inc. now owns 6,563,054 shares of the company’s stock worth $10,698,000 after purchasing an additional 180,105 shares during the last quarter. Gendell Jeffrey L lifted its holdings in Seelos Therapeutics by 6.7% in the third quarter. Gendell Jeffrey L now owns 1,859,635 shares of the company’s stock worth $4,481,000 after buying an additional 116,859 shares during the period. Two Sigma Advisers LP lifted its holdings in Seelos Therapeutics by 84.0% in the third quarter. Two Sigma Advisers LP now owns 1,771,100 shares of the company’s stock worth $4,268,000 after buying an additional 808,800 shares during the period. Geode Capital Management LLC lifted its holdings in Seelos Therapeutics by 26.5% in the third quarter. Geode Capital Management LLC now owns 1,721,677 shares of the company’s stock worth $4,149,000 after buying an additional 361,028 shares during the period. Finally, State Street Corp lifted its holdings in Seelos Therapeutics by 5.1% in the fourth quarter. State Street Corp now owns 1,660,304 shares of the company’s stock worth $2,706,000 after buying an additional 80,441 shares during the period. 38.73% of the stock is currently owned by institutional investors.

SEEL opened at $0.58 on Monday. The stock has a market cap of $61.01 million, a PE ratio of -0.93 and a beta of 2.62. The company has a quick ratio of 10.07, a current ratio of 10.07 and a debt-to-equity ratio of 0.31. Seelos Therapeutics has a 52 week low of $0.56 and a 52 week high of $5.48. The business’s fifty day simple moving average is $0.83 and its 200 day simple moving average is $1.33.

Seelos Therapeutics Company Profile (Get Rating)

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).

Read More

Get a free copy of the Zacks research report on Seelos Therapeutics (SEEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.